New PET tracer aims to light up hidden infections
NCT ID NCT05611892
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early study tested a new radioactive tracer called 18F-FDS in 16 people with suspected bacterial or fungal infections. The tracer is designed to light up infection sites on PET/CT scans, helping doctors see exactly where an infection is. The goal was to check how the tracer spreads in the body and whether it can accurately tell infected from healthy tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-Fluorodeoxysorbitol (18F-FDS) radioactive tracer
What this could lead to
If successful, this could lead to a new imaging method to better detect and locate certain bacterial and fungal infections in the body.
What could go wrong
This is a very early Phase 1 study with only 16 people, so it's mainly about safety and basic imaging. It may not work as hoped or may not be better than existing scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins Medical Institutions
Baltimore, Maryland, 21218, United States